Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ligustrum vulgare pollen is an allergen extract derived from the pollen of the common privet plant (Ligustrum vulgare). [1] It is used for diagnostic purposes to identify sensitization to privet pollen in individuals with respiratory allergies. The extract contains allergenic proteins, with the major allergen identified as Lig v 1, which belongs to the Ole e 1-like protein family. The product is administered via a skin prick test, where it targets and binds to IgE antibodies on mast cells in sensitized patients. [6] This interaction triggers a localized allergic reaction, confirming a diagnosis of privet pollen allergy, which can manifest as allergic rhinitis and asthma. [1] The product is available under the brand name 'Privet'.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ligustrum vulgare pollen.